Commercial License Grants. 6.2.1 Subject to Section 5.3 and the other terms and conditions of this Agreement, Rigel hereby grants to Novartis and its Affiliates an exclusive license, with the right to grant sublicenses, under the Rigel Technology and Rigel's interest in the Project Technology to make, have made, use, import, offer for sale and sell Products. 6.2.2 Subject to the terms and conditions of this Agreement, Rigel hereby grants to Novartis and its Affiliates a nonexclusive, non-transferable, royalty-free license under Rigel Core Technology only for confirmational screening and similar uses relating to Novel Validated Targets identified in the course of a Collaboration Project, it being understood that Novartis has the right to use such Technology for the purposes of further development, registration and commercialisation of Products.
Appears in 4 contracts
Samples: Collaboration Agreement (Rigel Pharmaceuticals Inc), Collaboration Agreement (Rigel Pharmaceuticals Inc), Collaboration Agreement (Rigel Pharmaceuticals Inc)